A Phase 3 interventional study of Tocilizumab and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 27 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-13.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 41st largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 84th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 70th largest by enrollment of the 141 interventional ones that give a count, is one of 10 that started in 2014, is one of 85 in phase 3, and was the 183rd registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase IIIb, open-label, single-arm study will evaluate the safety, efficacy, and tolerability of SC tocilizumab (RoActemra/Actemra) in monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants with active RA who are naive to tocilizumab. Participants will receive tocilizumab 162 milligrams (mg) subcutaneously weekly (QW) for 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.
Drug: Tocilizumab · Drug: Methotrexate · Drug: Non-Biologic DMARDs
Tocilizumab 162 mg will be administered subcutaneously QW.
Also known as: RoActemra, Actemra
Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12
CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
Time frame: Baseline, Week 12
Change From Baseline in Disease Activity Score 28 (DAS28)-Erythrocyte Sedimentation Rate (ESR) Score
DAS28-ESR was based on TJC, SJC, PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Percentage of Participants With American College of Rheumatology (ACR) Response
ACR response was assessed on the basis of percent improvement (20% for ACR20, 50% for ACR50, 70% for ACR70) in both TJC and SJC as well as at least three of the following: physician assessment of disease activity, PGA of disease activity, PGA of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and either ESR or C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, out of 68 and 66 assessed joints, respectively. PGA and physician assessments were scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity or pain. HAQ-DI was scored using participant responses to 20 questions assessing activities of daily living (ADLs), with total score scale of 0-3, where higher scores indicate increased functional disability. The percentage of participants meeting criteria for each level of ACR response was reported.
Time frame: Weeks 2, 4, 8, 12, 16, 20, 24
Percentage of Participants With European League Against Rheumatism (EULAR) Response
EULAR response was assessed by change from baseline and absolute DAS28-ESR score. EULAR response classification was as follows: Good (change \>1.2 with absolute score \</=3.2), Moderate (change \>1.2 with absolute score \>3.2 or change \>0.6 with absolute score \</=5.1), None (change \</=0.6 or absolute score \>5.1). DAS28-ESR was based on TJC, SJC, and PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. The percentage of participants meeting criteria for each level of EULAR response was reported.
Time frame: Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in CDAI at Weeks 2, 4, 8, 16, 20, and 24
CDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
Time frame: Baseline and Weeks 2, 4, 8, 16, 20, 24
Change From Baseline in Simplified Disease Activity Index (SDAI)
SDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, physician assessment of disease activity, and laboratory-derived C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total SDAI score range was 0-86, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in TJC
TJC was taken as the number of tender joints out of 28 assessed joints.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in SJC
SJC was taken as the number of swollen joints out of 28 assessed joints.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Percentage of Participants With At Least One Adverse Event Leading to Dosage Modification
The percentage of participants with at least one adverse event leading to dose/frequency reduction or temporary dose hold was reported.
Time frame: Baseline up to Week 24
Number of Participants With Neutralizing Anti-Tocilizumab Antibodies
Participants were evaluated for the presence of anti-tocilizumab antibodies. Confirmatory assays were performed in the case of a positive screen assay result.
Time frame: Baseline to FU Week 8 (up to 32 weeks overall)
Tocilizumab Concentration
Tocilizumab concentration was determined, averaged among all participants, and expressed in micrograms per milliliter (mcg/mL).
Time frame: Predose (30 minutes) at baseline; Weeks 12, 24; and FU Week 8 (up to 32 weeks overall)
Soluble Interleukin-6 Receptor (sIL-6R) Concentration
sIL-6R concentration was determined, averaged among all participants, and expressed in nanograms per milliliter (ng/mL).
Time frame: Predose (30 minutes) at baseline; Weeks 12, 24; and FU Week 8 (up to 32 weeks overall)
Change From Baseline in Patient Global Assessment of Disease Activity According to VAS
PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in Patient Global Assessment of RA-Related Pain According to VAS
PGA of RA-related pain was scored 0-100 mm on a VAS, where higher scores indicate greater perceived pain. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA-related pain.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in HAQ-DI Score
HAQ-DI consisted of 20 questions assessing ADLs in 8 domains (dress/groom, arise, eat, walk, reach, grip, hygiene) with each item rated 0 (no difficulty) to 3 (unable to do). The highest score recorded for any question in a domain determined the score for that domain, unless assistance was required. The total HAQ-DI score was the sum of domain scores divided by the number of domains answered/scored, for a single score range of 0-3, where higher scores indicate increased functional disability. Change from baseline was averaged among all participants. Negative values indicate improvement in ability to perform ADLs.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
Compliance With Treatment According to Percentage of Injections Administered
Participants were provided with diary cards to record home injections. Compliance with treatment was calculated individually for each participant as the actual number of injections as a percentage of the planned number of injections (up to the point of discontinuation for those who discontinued study treatment prematurely) and then averaged among all participants.
Time frame: Baseline up to Week 24
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
FACIT-F consisted of 40 questions/statements assessing chronic illness therapy with special emphasis on fatigue over the past 7 days, with each item rated 0 (not at all) to 4 (very much). During score calculations, negatively-worded item scales (e.g., "I have a lack of energy") were reversed so that higher scores indicated more favorable conditions. The total FACIT-F score was the sum of all item scores and ranged 0-160, and the brief FACIT-F score was the sum of 13 item scores and ranged 0-52, where higher scores indicate greater well-being. Change from baseline was averaged among all participants. Positive values indicate improvement in well-being.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24
| Milestone | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Started | 133 |
| Completed | 114 |
| Not completed | 19 |
| Withdrew: Anaphylaxis/serious hypersensitivity | 1 |
| Withdrew: Any other adverse event | 13 |
| Withdrew: Insufficient therapeutic response | 1 |
| Withdrew: Physician decision | 3 |
| Withdrew: Other | 1 |
| Milestone | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Started | 114 |
| Completed | 113 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
| units on a scale | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 24.9 ± 10.5 |
| Change at Week 12 | -16.6 ± 12.1 |
DAS28-ESR was based on TJC, SJC, PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
| units on a scale | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 5.0 ± 1.1 |
| Change at Week 2 | -1.4 ± 1.0 |
| Change at Week 4 | -2.1 ± 1.1 |
| Change at Week 8 | -2.8 ± 1.3 |
| Change at Week 12 | -2.9 ± 1.5 |
| Change at Week 16 | -3.2 ± 1.4 |
| Change at Week 20 | -3.3 ± 1.4 |
| Change at Week 24 | -3.3 ± 1.4 |
ACR response was assessed on the basis of percent improvement (20% for ACR20, 50% for ACR50, 70% for ACR70) in both TJC and SJC as well as at least three of the following: physician assessment of disease activity, PGA of disease activity, PGA of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and either ESR or C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, out of 68 and 66 assessed joints, respectively. PGA and physician assessments were scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity or pain. HAQ-DI was scored using participant responses to 20 questions assessing activities of daily living (ADLs), with total score scale of 0-3, where higher scores indicate increased functional disability. The percentage of participants meeting criteria for each level of ACR response was reported.
| percentage of participants | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| ACR20, Week 2 | 25.2 |
| ACR20, Week 4 | 51.5 |
| ACR20, Week 8 | 70.4 |
| ACR20, Week 12 | 70.8 |
| ACR20, Week 16 | 82.5 |
| ACR20, Week 20 | 77.2 |
| ACR20, Week 24 | 78.1 |
| ACR50, Week 2 | 8.7 |
| ACR50, Week 4 | 22.3 |
| ACR50, Week 8 | 46.4 |
| ACR50, Week 12 (n=120) | 51.7 |
| ACR50, Week 16 | 65.8 |
| ACR50, Week 20 | 64.9 |
| ACR50, Week 24 | 63.2 |
| ACR70, Week 2 | 0.8 |
| ACR70, Week 4 | 8.5 |
| ACR70, Week 8 | 24.0 |
| ACR70, Week 12 | 30.0 |
| ACR70, Week 16 | 44.2 |
| ACR70, Week 20 | 42.1 |
| ACR70, Week 24 | 47.4 |
EULAR response was assessed by change from baseline and absolute DAS28-ESR score. EULAR response classification was as follows: Good (change \>1.2 with absolute score \</=3.2), Moderate (change \>1.2 with absolute score \>3.2 or change \>0.6 with absolute score \</=5.1), None (change \</=0.6 or absolute score \>5.1). DAS28-ESR was based on TJC, SJC, and PGA of disease activity, and laboratory-derived ESR. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. The total DAS28-ESR score was transformed to a single score range of 0-10, where higher scores indicate increased disease activity. The percentage of participants meeting criteria for each level of EULAR response was reported.
| percentage of participants | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Week 2, Good | 29.1 |
| Week 2, Moderate | 47.2 |
| Week 2, None | 23.6 |
| Week 4, Good | 51.2 |
| Week 4, Moderate | 39.5 |
| Week 4, None | 9.3 |
| Week 8, Good | 78.4 |
| Week 8, Moderate (n=125) | 16.8 |
| Week 8, None | 4.8 |
| Week 12, Good (n=119) | 78.2 |
| Week 12, Moderate | 16.0 |
| Week 12, None | 5.9 |
| Week 16, Good | 87.5 |
| Week 16, Moderate | 9.2 |
| Week 16, None | 3.3 |
| Week 20, Good | 86.7 |
| Week 20, Moderate | 8.8 |
| Week 20, None | 4.4 |
| Week 24, Good | 87.7 |
| Week 24, Moderate | 9.6 |
| Week 24, None | 2.6 |
CDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
| units on a scale | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Change at Week 2 | -6.2 ± 8.4 |
| Change at Week 4 | -10.5 ± 9.8 |
| Change at Week 8 | -15.7 ± 11.0 |
| Change at Week 16 | -18.8 ± 11.5 |
| Change at Week 20 | -18.9 ± 11.7 |
| Change at Week 24 | -19.0 ± 11.7 |
SDAI was derived as the sum of the following: TJC, SJC, PGA of disease activity, physician assessment of disease activity, and laboratory-derived C-reactive protein level. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 mm and rounded to the nearest cm on a VAS, where higher scores indicate greater perceived disease activity. The total SDAI score range was 0-86, where higher scores indicate increased disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
| units on a scale | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 35.76 ± 20.71 |
| Change at Week 2 | -15.37 ± 16.71 |
| Change at Week 4 | -20.32 ± 19.24 |
| Change at Week 8 | -25.89 ± 20.88 |
| Change at Week 12 | -26.19 ± 23.21 |
| Change at Week 16 | -29.03 ± 21.15 |
| Change at Week 20 | -28.47 ± 21.26 |
| Change at Week 24 | -28.93 ± 20.93 |
TJC was taken as the number of tender joints out of 28 assessed joints.
| tender joints | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 8.8 ± 5.2 |
| Change at Week 2 | -2.1 ± 5.8 |
| Change at Week 4 | -3.5 ± 6.1 |
| Change at Week 8 | -5.8 ± 6.3 |
| Change at Week 12 | -5.5 ± 7.1 |
| Change at Week 16 | -6.7 ± 6.9 |
| Change at Week 20 | -6.7 ± 6.5 |
| Change at Week 24 | -7.1 ± 5.8 |
SJC was taken as the number of swollen joints out of 28 assessed joints.
| swollen joints | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 6.8 ± 5.5 |
| Change at Week 2 | -2.3 ± 4.3 |
| Change at Week 4 | -3.1 ± 4.7 |
| Change at Week 8 | -4.8 ± 5.1 |
| Change at Week 12 | -5.3 ± 5.3 |
| Change at Week 16 | -5.9 ± 5.2 |
| Change at Week 20 | -6.0 ± 5.4 |
| Change at Week 24 | -5.4 ± 5.3 |
The percentage of participants with at least one adverse event leading to dose/frequency reduction or temporary dose hold was reported.
| percentage of participants | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Dose/Frequency Reduced Due to Adverse Event | 18.80 |
| Dose Held Due to Adverse Event | 27.07 |
Participants were evaluated for the presence of anti-tocilizumab antibodies. Confirmatory assays were performed in the case of a positive screen assay result.
| participants | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Number of Participants With Neutralizing Anti-Tocilizumab Antibodies | 1 |
Tocilizumab concentration was determined, averaged among all participants, and expressed in micrograms per milliliter (mcg/mL).
| mcg/mL | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 0.6 ± 0.3 |
| Week 12 | 47.4 ± 28.1 |
| Week 24 | 48.0 ± 27.2 |
| FU Week 8 | 32.8 ± 19.3 |
sIL-6R concentration was determined, averaged among all participants, and expressed in nanograms per milliliter (ng/mL).
| ng/mL | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 37.0 ± 12.7 |
| Week 12 | 509.4 ± 138.7 |
| Week 24 | 520.2 ± 156.4 |
| FU Week 8 | 166.0 ± 203.5 |
PGA of disease activity was scored 0-100 mm on a VAS, where higher scores indicate greater perceived disease activity. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA disease activity.
| mm | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 53.2 ± 21.1 |
| Change at Week 2 | -6.8 ± 18.6 |
| Change at Week 4 | -20.3 ± 21.3 |
| Change at Week 8 | -24.6 ± 25.8 |
| Change at Week 12 | -30.3 ± 25.5 |
| Change at Week 16 | -32.3 ± 23.9 |
| Change at Week 20 | -32.2 ± 27.1 |
| Change at Week 24 | -34.3 ± 24.8 |
PGA of RA-related pain was scored 0-100 mm on a VAS, where higher scores indicate greater perceived pain. Change from baseline was averaged among all participants. Negative values indicate improvement/reduction in RA-related pain.
| mm | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline | 54.8 ± 22.1 |
| Change at Week 2 | -9.1 ± 20.8 |
| Change at Week 4 (n=128) | -22.5 ± 24.4 |
| Change at Week 8 | -28.9 ± 26.6 |
| Change at Week 12 | -32.8 ± 27.5 |
| Change at Week 16 | -35.6 ± 25.9 |
| Change at Week 20 | -35.0 ± 26.7 |
| Change at Week 24 | -37.8 ± 26.3 |
HAQ-DI consisted of 20 questions assessing ADLs in 8 domains (dress/groom, arise, eat, walk, reach, grip, hygiene) with each item rated 0 (no difficulty) to 3 (unable to do). The highest score recorded for any question in a domain determined the score for that domain, unless assistance was required. The total HAQ-DI score was the sum of domain scores divided by the number of domains answered/scored, for a single score range of 0-3, where higher scores indicate increased functional disability. Change from baseline was averaged among all participants. Negative values indicate improvement in ability to perform ADLs.
| units on a scale | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Baseline (n=133) | 1.2 ± 0.6 |
| Change at Week 2 | -0.1 ± 0.4 |
| Change at Week 4 | -0.3 ± 0.5 |
| Change at Week 8 | -0.5 ± 0.5 |
| Change at Week 12 | -0.5 ± 0.6 |
| Change at Week 16 | -0.6 ± 0.6 |
| Change at Week 20 | -0.6 ± 0.6 |
| Change at Week 24 | -0.6 ± 0.6 |
Participants were provided with diary cards to record home injections. Compliance with treatment was calculated individually for each participant as the actual number of injections as a percentage of the planned number of injections (up to the point of discontinuation for those who discontinued study treatment prematurely) and then averaged among all participants.
| percentage of injections | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Compliance With Treatment According to Percentage of Injections Administered | 86.78 ± 23.04 |
FACIT-F consisted of 40 questions/statements assessing chronic illness therapy with special emphasis on fatigue over the past 7 days, with each item rated 0 (not at all) to 4 (very much). During score calculations, negatively-worded item scales (e.g., "I have a lack of energy") were reversed so that higher scores indicated more favorable conditions. The total FACIT-F score was the sum of all item scores and ranged 0-160, and the brief FACIT-F score was the sum of 13 item scores and ranged 0-52, where higher scores indicate greater well-being. Change from baseline was averaged among all participants. Positive values indicate improvement in well-being.
| units on a scale | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Brief Score, Baseline (n=133) | 32.9 ± 11.1 |
| Brief Score, Change at Week 2 | 3.4 ± 6.9 |
| Brief Score, Change at Week 4 | 5.7 ± 8.3 |
| Brief Score, Change at Week 8 | 6.6 ± 8.0 |
| Brief Score, Change at Week 12 | 7.6 ± 7.8 |
| Brief Score, Change at Week 16 | 7.9 ± 9.7 |
| Brief Score, Change at Week 20 | 8.0 ± 9.1 |
| Brief Score, Change at Week 24 | 8.4 ± 8.5 |
| Total Score, Baseline | 106.8 ± 23.6 |
| Total Score, Change at Week 2 | 6.9 ± 14.0 |
| Total Score, Change at Week 4 | 13.0 ± 16.6 |
| Total Score, Change at Week 8 | 15.1 ± 16.2 |
| Total Score, Change at Week 12 | 17.1 ± 16.2 |
| Total Score, Change at Week 16 | 18.0 ± 20.1 |
| Total Score, Change at Week 20 | 18.6 ± 19.8 |
| Total Score, Change at Week 24 | 20.1 ± 19.3 |
Collected over Baseline up to FU Week 8 (up to 32 weeks overall). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab Alone or Combined With Methotrexate or Other DMARD | — | 12/133 (9%) | 120/133 (90.2%) |
| Event | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| HypertensionVascular disorders | 2/133 |
| PneumoniaInfections and infestations | 2/133 |
| Acute psychosisPsychiatric disorders | 1/133 |
| Anaphylactic reactionImmune system disorders | 1/133 |
| Back painMusculoskeletal and connective tissue disorders | 1/133 |
| ConstipationGastrointestinal disorders | 1/133 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/133 |
| HeadacheNervous system disorders | 1/133 |
| Infectious pleural effusionInfections and infestations | 1/133 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/133 |
| Event | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| NasopharyngitisInfections and infestations | 20/133 |
| HypertensionVascular disorders | 17/133 |
| NauseaGastrointestinal disorders | 11/133 |
| Upper respiratory tract infectionInfections and infestations | 10/133 |
| RashSkin and subcutaneous tissue disorders | 10/133 |
| Alanine aminotransferase increasedInvestigations | 9/133 |
| HeadacheNervous system disorders | 9/133 |
| PruritusSkin and subcutaneous tissue disorders | 8/133 |
| Injection site erythemaGeneral disorders | 7/133 |
| Neutrophil count decreasedInvestigations | 7/133 |
Intent-to-Treat (ITT) Set: all participants who were treated with at least one dose of SC tocilizumab.
| Age, Continuous(years) | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Mean | 55.9 ± 12.0 |
| Sex: Female, Male(Participants) | Tocilizumab Alone or Combined With Methotrexate or Other DMARD |
|---|---|
| Female | 108 |
| Male | 25 |
Ran from May 2014 to primary completion in Sep 2016, 27 months.
Results were first posted in Apr 2018, 1 year 7 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 27 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab